Khizar Hayat: We achieved our goal through the prayers of the well wishers and the persisitent efforts of the physician who is treating my son to persuade the phamaceutical companies for release of the drugs on compassionate grounds. Although AMGEN did not responded positively to his request and our petition, another pharmacutical company Pfizer agreed to release their drug Inotuzumab for the treatment of my son on compassionate grounds. The medicine was received in the pharmacy of the Hospital, the staff was trained to administer the drug and the treatment started on 25th of October.
I would like to thank everyone who supported our petition and request them to pray for the recovery of my son.
(ALLAH SHAFI) My son Zeeshan Khizar Hayat was diagnosed for Acute Lymphoblastic Leukemia in 1996 at the age of 9 years. He received therapy with high risk ALL porotocol. The First Relapse occurred in February 2000 and he received Re-induction therapyThe Second relapse was identified on January 31, 2009 and was managed with a Dana Farber regimen which was followed by CNS phase thereafter with irradiation , multiple intrathecal chemotherapy doses. He underwent Allogenic Stem Cell Transplant with stem cells donated by sister. The Third relapse was identified on December 3, 2012 He received further salvage chemotherapy using the Hyper CVAD regimen. He achieved Complete Remission in May. Unfortunately during the routine follow on September 9, 2013 he was identified for Fourth Relapse. Our options are very restricted now. Unfortunately Ontario does not have any ALL specific Clinical Trails from which Zeeshan can benefit. We have been advised and also got the information from internet that AMGEN has developed a drug called BLINATUMOMAB which is highly effective for patients with multiple relapses of ALL. As this drug is still undergoing Clinical Trails mostly in USA, it is not available in Canada and the eligibility criteria might be restricted to patients with two relapses only.Keeping in view the gravity of the situation, and urgency I plead to AMGEN to provide Single Patient Access to my son for Blinatumomab and save his life, even if he is not eligible for the Clinical Trials in Ontario Canada